Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:22:34.834Z.
Calculation as of: 2026-10-06T18:22:34.834Z.
Quote observation: 2026-10-06T18:19:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1195b951add05ab4c37664b10382d427b1d38f05de7a164f71fe4d518fffb76
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$83.61M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.56M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.85M
Price/FCF Ratio
N/A
TTM Avg
17.74
3Y Avg
16.00
5Y Avg
17.53
Market Cap
$82.19M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProMIS Neurosciences, Inc. (PMN) | $83.58M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.61M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.56M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.85M | N/A | 17.74 | 16.00 | 17.53 |
| LENSAR Inc (LNSR)vs › | $82.78M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.64M | N/A | 112.11 | 112.11 | 112.11 |
| Humacyte, Inc. (HUMA)vs › | $82.49M | N/A | N/A | N/A | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.19M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.14M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.90M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
